Editas Medicine (EDIT) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Strategic focus and pipeline updates

• Strategy centers on three pillars: advancing reniz-cel for sickle cell disease, building in vivo gene editing capabilities, and monetizing intellectual property.

• Reniz-cel shows strong efficacy, with patients experiencing no vaso-occlusive events and correction of anemia to normal hemoglobin levels.

• Over 20 patients have been dosed, with full enrollment of adult and adolescent cohorts completed ahead of schedule.

• In vivo efforts prioritize functional upregulation over knockdown, targeting diseases with poor or no standard of care and leveraging rapid biochemical readouts.

• In vivo proof of concept is expected by year-end, with details on editing degree and market size to be shared, but specific targets withheld for competitive reasons.

Technology and differentiation

• Focus on upregulation as a key differentiator, validated in humans using Cas12a enzyme.

• Target selection leverages large-scale human genetic datasets to de-risk and identify optimal disease targets.

• Delivery strategy centers on lipid nanoparticles (LNPs), with AAV deprioritized to focus resources.

• Development timelines for in vivo programs are measured in years, with manufacturing scale-up as a critical path.

Reniz-cel clinical progress and competitive positioning

• Reniz-cel data show durable correction of anemia and absence of vaso-occlusive events, differentiating it from competitors.

• Manufacturing and CMC processes have been optimized, with timelines tightly managed.

• Year-end updates will include more patient data and longer follow-up, aiming to match or exceed benchmarks set by competitors for regulatory filings.